

CytoSorbents™

Working to save lives **together.**

NASDAQ: CTSO

Investor Presentation

November 2026 - Updated

CytoSorbents™

Safe Harbor Statement

Statements in this presentation include forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this presentation represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, the impact of geopolitical events including the recent war in Iran, our ability to successfully obtain U.S. FDA and Health Canada regulatory approval and marketing authorization, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, including our ability to meet our financial obligations and comply with the covenants under our existing debt agreement, our ability to fund and develop new and existing research and development programs, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges from Net Loss and Net Loss Per Share, respectively. Additionally, we use the non-GAAP financial measure of Negative Free Cash Flow which consists of net cash used in operating activities plus net cash used in investing activities. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements. For a reconciliation of non-GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.

CytoSorbents Overview

- U.S.-based medical device company (Nasdaq: CTSO) specializing in blood purification to treat life-threatening conditions in the intensive care unit and cardiac surgery with its proprietary, biocompatible, porous polymer bead technology

- **CytoSorb** is the leading CE-mark approved extracorporeal cytokine adsorber in the European Union and is manufactured by CytoSorbents in the U.S.
  - Distributed in more than 70 countries worldwide, **with 300,000+ human treatments to date**
  - Approved for:
    - Cytokine Removal
    - Bilirubin and Myoglobin Removal
    - Ticagrelor and Rivaroxaban removal during cardiothoracic surgery
  - $37.5M in sales (ttm 9/30/26) with 73% gross margins – High margin razorblade
  - Strategic Partnerships with Fresenius Medical Care, B Braun, Aferetica, and Terumo Cardiovascular
  - U.S. government support for the technology with ~$50M in grants, contracts, and other non-dilutive funds from NIH, NHLBI, DARPA, DHA, US Army, US Air Force, JPEO-CBD, USSOCOM, etc.

- DrugSorb ATR Pursuing U.S. FDA and Health Canada approval of DrugSorb-ATR to reduce perioperative bleeding risk in patients on blood thinners during cardiac surgery as a 2-time FDA Breakthrough Device

- **HEMODEFEND-BGA** Funded by $16M in DoD funding – targeting the holy grail of universal blood products

- Achieved positive operating cash flow of +$43K (less $251K in restructuring costs) in Q3 2026. Goal is to sustain a range of operating cash flow breakeven with a target of future profitability





The Power of the Bead

Hemocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration



- Robust platform technology that rapidly removes a broad range of substances from whole blood and plasma
- Solid state porous polymer chemistry that does not use labile and expensive ligands, antibodies, cells, or biologics
- 20 issued U.S. patents and multiple patents issued and pending worldwide

CytoSorbents™

Products are “Plug and Play” Compatible

Compatible with Existing Blood Pump Infrastructure In Hospitals Today

Dialysis or CRRT
(Continuous Renal Replacement Therapy)



Hemoperfusion
(Standalone Treatment)



ECMO
(Extracorporeal Membrane Oxygenation)



CPB
(Cardiopulmonary Bypass)



CytoSorbents™

We are an Innovation Leader in Acute Care Blood Purification

Commercially Available Products		
CytoSorb®	Sepsis | Critical care | Cardiac surgery	E.U., FDA EUA
ECOS-300CY®	Ex-vivo organ perfusion for transplant	E.U.
VETRESQ®	Veterinarian critical care	U.S.
PuriFi®	Hemoperfusion pump	E.U.
HotSwap™	Rapid device interchange system	E.U.

Pipeline Product	Application	Pre-Clinical	Pilot	Pivotal	Status
DrugSorb™ ATR	Removal of antithrombotic drugs	2 FDA Breakthrough Device Designations			US De Novo Submission – Expected early 2027
HemoDefend BGA	Universal Blood Products				Clinical trials expected 2027-28
CytoSorb-XL	Successor to CytoSorb				Pipeline
ContrastSorb	CT Imaging and interventional radiology procedures				Pipeline

CytoSorbents™

Four Independent Key Drivers of Value Creation



CytoSorbents™

CytoSorb

Our Core Business





 CytoSorb is E.U. CE Mark approved but not yet cleared or approved in the U.S./Canada

CytoSorb is Expanding the Dimension of Blood Purification

CytoSorb is a powerful blood purification technology CE-mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It removes many substances that dialysis cannot.

Dialysis is designed to work like the kidney



Small Molecules and
Water soluble substances

Urea, Ammonia
Electrolytes
Water
Water-soluble drugs



CytoSorb is designed to work like the liver



Large Molecules and
Fat soluble substances

Cytokines
Inflammatory mediators
Bacterial toxins
Liver toxins
Proteins and peptides
Fat-soluble drugs



CytoSorb has 7 football fields of surface area to bind toxins versus
¾ of a ping pong table for a dialyzer

CytoSorbents™

CytoSorb is approved in the EU but is not yet cleared/approved in the US or Canada

Uncontrolled Massive Inflammation - the Heart of Critical Illness

- Acute inflammation is the body's mechanism to fight injury and infection
- However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death



- Severe inflammation is the common thread amongst most critical illnesses and impacts up to 60% of patients in the ICU. Is directly correlated to increased severity of illness, organ failure, and mortality

CytoSorb removes cytokines and other inflammatory toxins that fuel the fire of this deadly inflammation

CytoSorbents™

Targets Deadly Conditions That Afflict Millions of People

Critical Care

Removes the "fuel to the fire" of massive uncontrolled inflammation that is often associated with organ failure and death



Sepsis



Surgical Complications



Influenza



Burn Injury



COVID-19



Cytokine Release Syndrome



Lung Injury



Liver Failure



Trauma



Pancreatitis

Cardiothoracic Surgery

Reduces inflammation and blood thinners, targeting reduction in complications of cardiac surgery like sepsis, bleeding, shock, and others



Life-threatening bleeding due to anti-thrombotic "blood thinners"



Infective Endocarditis



High Risk Procedures

CytoSorbents™

CytoSorb is approved in the EU but is not yet cleared/approved in the US or Canada

CytoSorbents is Leading a New Era in Sepsis Treatment



For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock – the cause of nearly 1 in 5 deaths worldwide - by complementing traditional antibiotics with CytoSorb blood purification





Antibiotics treat the infection



CytoSorb treats the deadly inflammatory response by removing the “fuel to the fire” that causes a system crash



CytoSorbents™

The Key to Success: Right Patient, Right Timing, Right Dosing





Before and after treatment of a patient with liver disease

CytoSorbents™

CytoSorb Attacks Sepsis in a Comprehensive & Multi-faceted Way

- Reduce inflammation by reducing a broad range of cytokines (cytokine storm) & other inflammatory mediators
- Bacterial toxins (hemolysins, super antigens, etc)
- Reversal of shock (macro) & improvement in microcirculation and lactate clearance 
- Improve respiratory function and gas exchange
- Protect the endothelium, promote repair of capillary leak, and **enable excess fluid removal** 
- Improve or protect organ function (e.g. shock, ARDS, acute kidney injury, liver dysfunction)
- Re-establish proper leukocyte trafficking to prevent cell-mediated organ injury

CytoSorb is very unique in its broad range of activity

CytoSorbents™

CytoSorb Core Treatment Goals

A wealth of published, peer-reviewed studies support the broad mechanisms of action of CytoSorb that enable a comprehensive and multi-faceted attack on septic shock – from beginning to end

CytoSorb helps to achieve the
Core Treatment Goals in Septic Shock to
Prevent or Treat Organ Failure and
Help Patients Recover

- Break the vicious cycle of massive, uncontrolled inflammation
- Stabilize the patient (reverse shock, improve oxygenation, restore oxygenated blood flow, etc)
- Promote the repair of capillary leak
- Actively remove excessive fluid and reduce fluid overload in organs



CytoSorbents™

CytoSorb Commercialization Focus

- We sell CytoSorb in more than 70 countries worldwide with more than 300,000 treatments to date
- Sell Direct in Germany and 9 other countries & through Distributors and partners in the remainder

Estimated Revenue By Market



2025 Revenue



* Austria, Switzerland, Poland, Netherlands, England, Wales, North Ireland, Scotland, Ireland

A History of Strong Annual Sales Growth



Following the resolution of the pandemic and the devaluation of the Euro to USD to parity in 2022, core sales have rebounded and continued to grow

CytoSorbents™

Q3 2026 Performance

Margin expansion and cost discipline cut adjusted EBITDA loss 86%

Revenue
$9.7M
▲ 3%
vs. $9.5M in Q3 2025

Gross margin
75%
▲ 500 basis pts
vs. 70% in Q3 2025

Operating expenses
$8.5M
▼ 11%
vs. $9.5M in Q3 2025

Operating loss
($1.2M)
59% improvement
vs. ($2.9M) in Q3 2025

Net loss
($1.8M)
42% improvement
vs. ($3.2M) in Q3 2025

Adjusted EBITDA loss*
($0.3M)
86% improvement
vs. ($2.0M) in Q3 2025

Adjusted EBITDA loss by quarter*
2026, $ millions



Improved every quarter of 2026

* Non-GAAP measure; see the reconciliation in the appendix. Quarterly figures rounded.

CytoSorbents™

Operating Cash Flow Breakeven Achieved in Q3 2026



Fundamental improvements drive breakeven

- +$43K operating cash flow in Q3, excluding ~$251K of restructuring-related payments
- Total Q3 cash burn of ~$0.2M; $5.7M of cash, cash equivalents and restricted cash at September 30
- Year-to-date cash used in operations down 73% to $2.0M
- Focus now shifts to remaining at or near breakeven; quarterly results may fluctuate with timing of revenue, collections and working capital

* *Negative Free Cash Flow = Net cash used in operating activities plus net cash used in investing activities*

CytoSorbents™

Closed At-the-Market Equity Financing with Debt Restructuring

A $6.25M financing backed by Key Stakeholders

Equity financing
$6.25M
$4.0M new cash
+ $2.25M of debt exchanged for stock

Total debt
$12.25M
▼ 30%
vs. $17.5M before the transaction

Interest savings
~$0.7M
Est. over next 12 months
from lower debt principal

Debt maturity
July 2028
▲ Extended 1 year
interest-only through March 2028

Our existing shareholders

Together with management and the Board, bought ~75% of the $4.0M offering

Our Board and management

Invested their own money alongside shareholders, at $5.18 per share

Avenue, our lender

Took $2.25M of its loan in stock and extended our maturity and interest-only period

Option to convert additional $3.0M of debt to equity at $6.92 per share and $3.125M at $8.65 per share, retiring up to $6.125M in debt

CytoSorbents™

The Opportunity of DrugSorb™ ATR





DrugSorb-ATR is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale

CytoSorbents™

Blood Thinners and Cardiac Surgery



- Tens of millions of patients globally take Direct Oral Anticoagulants (e.g, DOACs like Eliquis® and Xarelto®) and antiplatelet agents (e.g, Brilinta®) either chronically or acutely to reduce risk of heart attack, stroke, and other serious thrombotic complications

- Each year, an estimated 10% will require emergent or urgent surgery, including cardiac surgery
  - ~5-10% of emergency cardiac surgeries involve patients on chronic DOAC therapy
  - ~5-10% of heart attack patients on antiplatelet agents are not eligible for a stent and require CABG surgery



- Blood thinners significantly increase the risk of perioperative bleeding in cardiac surgery. Delay of surgery for multiple days to "washout" the drug is typically recommended to reduce this risk

- However, waiting for drug washout may increase the risk of poor patient outcomes (e.g. thrombotic events, clinical instability, and sudden death) and wastes valuable hospital resources

- DrugSorb-ATR has received two FDA Breakthrough Designations, highlighting the lack of available effective therapies to address this pervasive and serious problem by removing the drug

- Seeking two parallel paths to De Novo marketing approval for DOACs and Brilinta®

Brilinta® , Eliquis®, and Xarelto® are trademarks of AstraZeneca, Bristol-Myers Squibb, and Bayer, respectively

CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

Brilinta® and the Use Case for DrugSorb™ ATR











DrugSorb™ ATR



weekly plan						
monday	tuesday	wednesday	thursday	friday	saturday	sunday
	X	X	X	X	X	





DrugSorb-ATR works during surgery to remove free drug, helping to reduce or prevent serious perioperative bleeding complications that would otherwise take days to achieve

CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

The Pivotal STAR-T RCT Paper Is Now Published

Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding

Michael J. Mack, MD,[a] Richard Whitlock, MD,[b] Michael W. A. Chu, MD,[c] Bradley Taylor, MD,[d] Elias A. Zias, MD,[e] David Liu, MD,[f] Adam N. Protos, MD,[g] Chris Rokkas, MD,[h] Marc Pelletier, MD,[i] Chun W. Choi, MD,[j] Tarit Saha, MD,[k] Frank W. Sellke, MD,[l] David J. Schneider, MD,[m] Vinod H. Thourani, MD,[n] James Douketis, MD,[o] Cyril David Mazer, MD,[p] Weihong Fan, MS,[q] Efthymios N. Deliargyris, MD,[q] and Charles Michael Gibson, MD,[r,s] on behalf of the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR-T) Investigators

ABSTRACT

Objective: Patients on ticagrelor who are undergoing cardiac surgery before completing guideline-recommended washout are at high risk for severe bleeding. This study evaluated whether a novel drug removal device reduces bleeding in patients operated within 2 days from ticagrelor discontinuation.

Methods: Eligible patients were randomized 1:1 to intraoperative DrugSorb-ATR or sham control. Primary safety end point was adverse events at 30 days. Efficacy was assessed by composite end points comprising bleeding events using Universal Definition of Perioperative Bleeding (UDPB) and 24-hour chest tube drainage (CTD) in the overall and isolated coronary artery bypass grafting (CABG) populations with a hierarchical win ratio (WR) method.

Results: In total, 140 patients were randomized; 132 had surgery and received a study device; and 92% were isolated CABG. Mean age was 65 ± 5 years, and 15% were female. The primary safety end point was met, with similar adverse events reported between groups. The primary efficacy end point was not met in the overall or CABG populations (Win ratio [WR], 1.07; 95% CI, 0.72-1.58; $P = .748$ and WR, 1.33; 95% CI, 0.86-2.04; $P = .202$ respectively). The supplementary efficacy end point was met in the CABG population (WR, 1.59; 95% CI, 1.02-2.46, $P = .041$) with significant reductions also shown in large CTD bleeding events ($P = .016$) and major bleeding, a composite of severe bleeding events or 24-hour CTD ≥1 L ($P = .041$). The number needed to treat to prevent a major bleed was 6.

Conclusions: Intraoperative use of DrugSorb-ATR is safe in patients operated within 2 days of ticagrelor discontinuation. Although the primary end point was not met in the overall population, there were significant reductions in severe bleeding events in the prespecified CABG population. (J Thorac Cardiovasc Surg 2026;■:1-10)



Major bleeding, a composite of severe bleeding events (UDPB ≥3) or 24-hour CTD ≥ 1 L.

CENTRAL MESSAGE

Intraoperative DrugSorb-ATR use for ticagrelor removal is safe and can reduce the severity of bleeding after isolated CABG in patients operated within 2 days of drug discontinuation.

PERSPECTIVE

Antithrombotic drug–related perioperative bleeding risk is a major clinical issue frequently resulting in surgical delays. The present study showed that the intraoperative use of a device that can remove ticagrelor from blood was safe and reduced severe bleeding events among patients undergoing CABG within 2 days of ticagrelor discontinuation.



Major bleeding, a composite of severe bleeding events (UDPB ≥3) or 24-hour CTD ≥ 1 L.

CENTRAL MESSAGE

Intraoperative DrugSorb-ATR use for ticagrelor removal is safe and can reduce the severity of bleeding after isolated CABG in patients operated within 2 days of drug discontinuation.

Although the primary endpoint including both CABG and high-risk cardiac surgeries was missed due to imbalances in the study, in the pre-specified CABG subgroup (main use population):

- Significant 16.3% absolute reduction in major bleeding (13.7% treatment vs 30.0% control, p= 0.041)
- 57.7% relative reduction in major bleeding
- NNT = 6: Six patients need to be treated to prevent 1 serious bleeding event

Mack, M, et al. J Thorac Cardiovasc Surg. 2026. Online ahead of print

CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

Key Real-World Evidence Presented At ESC 2026

ESC CONGRESS 2026 MUNICH

Intraoperative Ticagrelor Removal To Reduce Bleeding After Urgent CABG
Matched Comparison Of Patient-Level Observational Data

STAR Registry

U. Zeymer[1], M. Schoerghuber[2], T. Kuenzer[3], M. Thielmann[4], M. Dalen[5], G. Schlachtenberger[6], F. de Somer[7], C. Mayer[8], TJ. Donovan[9], M. Bernardi[10], N. Marczin[11], R. Tircoveanu[12], D. Wendt[13], M. Schmoeckel[14], A. Berghold[3]

- At ESC 2026, the largest patient-level matched analysis was presented comparing bleeding severity in 587 urgent CABG patients on ticagrelor with CytoSorb (n=198) from the STAR Registry or without (n=389) from a previously published individual patient data meta-analysis*
- The independent analysis showed:
  - A significant 37% relative reduction in BARC-4 severe bleeding with CytoSorb use (21.8% vs 34.5% in controls; p=0.002)
  - Number of patients needed to be treated (NNT) with CytoSorb to prevent one severe bleeding event after urgent CABG was eight (8) and consistent with the NNT of 6 seen in the STAR-T trial
  - Significant reductions in 24-hour chest tube drainage (p=0.039) and red blood cell transfusions (p=0.003) with CytoSorb use was also observed
  - No serious device-related adverse events were reported

Endpoint outcomes



Secondary outcome analyses showed that the device significantly reduced:

- 24-hour chest tube drainage (-125.4 mL; 95% CI: -244.2, -6.6, p=0.039)
- Red blood cell transfusions within 48 hours of CABG (-1.19 units; 95% CI: -1.97, -0.38, p=0.003)
- No serious adverse device-related events

Findings reinforce results from STAR-T trial and are expected to form a core component of additional real-world evidence proposed by FDA in last year's appeal to support probable benefit in new De Novo submission and quintuple (5x) the number of treated patients (n=249) and increases control patients to 450

 | * Schoerghumber, M., et al., Eur J Cardiothorac Surg (2024); 66(1): ezae265

CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

FDA Regulatory Path for DrugSorb-ATR and Brilinta®

Planning new De Novo Submission to FDA, where standard of approval is:

Probable Benefit Outweighs Probable Risk

Targeting New De Novo Submission in early-2027
Potential Marketing Approval in mid-2027

Aligning with FDA on type of data and experimental model → Additional Mechanistic Data

Data reinforces STAR-T results and increases treated patients in new De Novo by 5x (n=249) → New Real World Efficacy Analysis



CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

Large Total Addressable Market

DrugSorb™ ATR

Initial Opportunity



- U.S. & CAN Ticagrelor Removal in CABG

Near-Term Opportunity >$600M



- Expansion of U.S. & CAN Ticagrelor Removal in CABG
- DOAC Removal in CABG

Future Opportunity
$1-2 Billion



- U.S. & CAN Ticagrelor Removal in CABG
- DOAC Removal in CABG
- DOAC Removal in Hospital-Wide Applications

CytoSorbents™

DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved

Unlocking the Strategic Value of

HEMODEFEND-BGA

For Universal Blood Products





HemoDefend-BGA is a preclinical device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale

CytoSorbents™

Multiple Blood Products. Millions of Units. One Compatibility Platform

HemoDefend is a filter platform that removes anti-A and anti-B blood group antibodies that can be used for plasma and platelets to create “Universal” products that can be given to any patient regardless of blood type – the “Holy Grail” for plasma and platelets



PLATELETS

- **~2.2 million units transfused annually in the U.S.**
- Short shelf life and frequent ABO-mismatched use create a strong compatibility need



PLASMA

- **~1.9 million units transfused annually in the U.S.**
- ABO compatibility remains an important constraint on inventory and use



ADDITIONAL OPPORTUNITIES

- Whole blood
- Freeze-dried plasma
- Military & emergency medicine
- International markets
- Plasma processing applications

CytoSorbents™

HemoDefend-BGA is a development stage device in the U.S. and Canada and not yet cleared/approved

Simple By Design



GRAVITY DRIVEN
No capital equipment

~5–10 MINUTES
Simple processing step

SCALABLE
Designed to integrate into existing blood-center workflows

UNIVERSAL
Low-titer, broadly compatible blood

PLATFORM TECHNOLOGY
Same core technology can be applied across multiple blood products and compatible with freeze-dried formats

CytoSorbents™

HemoDefend-BGA is a development stage device in the U.S. and Canada and not yet cleared/approved

Designed for Broad Use Across the Blood Ecosystem



Blood Centers

Simplify the blood supply and create more broadly compatible products



Hospitals

Improve access to compatible blood products and reduce reliance on off-type transfusions



Emergency & Military

Simplified logistics and rapid administration of life-saving blood products when blood type is unknown or time is critical



Plasma Processing

Reduce ABO antibody constraints in plasma-derived products

CytoSorbents™

HemoDefend-BGA is a development stage device in the U.S. and Canada and not yet cleared/approved

HemoDefend Represents Significant Unrecognized Value

~$16 MILLION IN NON-DILUTIVE FUNDING TO DATE

- Major support from the U.S. government and the Department of Defense (War)
- Discussions ongoing for additional non-dilutive funding from the US Govt to fund clinical trials, manufacturing scale up, through approval.

POSITIVE FDA ENGAGEMENT

- Recent FDA feedback provided clarity on relatively straightforward clinical and regulatory path to potential FDA marketing approval

LEADING ORGANIZATIONS

Testing, Validation, or Engagement with:

- **Leading Blood Centers, like NHSBT**
- **Major Government Agencies**
- **Blood transfusion Industry Companies**

GROWING STRATEGIC INTEREST

Major blood-management companies have engaged around potential development support, strategic investment, commercialization capabilities, and other forms of collaboration.

First FDA BLA approved for Freeze Dried Plasma, paving way for “Universal Plasma” holy grail

HemoDefend-BGA is a Valuable Asset that Has Significant Strategic and Funding/Monetization Possibilities

CytoSorbents™

HemoDefend-BGA is a development stage device in the U.S. and Canada and not yet cleared/approved

Four Independent Value Drivers. One Uncommon Value



CytoSorbents™

CytoSorbents Investment Thesis: Risk-Reward Asymmetry

- CytoSorbents has four largely distinct pathways to value creation over the next 6–18 months, each of which could be significant catalysts for upside potential
  1) Achieving sustainable operating cash-flow breakeven
  2) Driving the high-margin CytoSorb franchise to stronger growth
  3) Opening the U.S. market through DrugSorb-ATR
  4) Unlocking the strategic value of HemoDefend-BGA

- Meanwhile, the company has been executing on its strategy to reduce its cost structure, preserve cash & create a pathway toward financial self-sustainability. Q3 2026 continued that progress, including achieving: 75% product gross margins, significantly improved operating performance, reduced adjusted EBITDA & positive operating cash flow

- We believe our current market valuation discounts our core business and the potential for significant near-term value creation with other major value drivers, while reflecting an asymmetric overemphasis on financial risks that we have now resolved

We believe the combination of our high margin single use disposables that addresses a global unmet need, with multiple independent near-term catalysts, and improving underlying fundamentals makes CTSO a compelling investment opportunity

CytoSorbents

NASDAQ: CTSO

Company Contacts:

Dr. Phillip Chan - CEO
pchan@cytosorbents.com

Peter Mariani – CFO
pmariani@cytosorbents.com







CytoSorbents™